Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Basun

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Dementia and Geriatric Cognitive Disorders|November 24, 1999
A follow-up study of the family with the Swedish APP 670/671 Alzheimer's disease mutationL O Wahlund, H Basun, O Almkvist, et al.
Annals of the New York Academy of Sciences|July 27, 2000
Inherited frailty. ApoE alleles determine survival after a diagnosis of heart disease or stroke at ages 85+E H Corder, H Basun, L Fratiglioni, et al.
Neuroreport|May 20, 1998
EEG slowing and cerebrospinal fluid tau levels in patients with cognitive declineV Jelic, M Blomberg, T Dierks, et al.
Neuroscience Letters|June 27, 1997
Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau proteinM Lindh, M Blomberg, M Jensen, et al.
Neuroscience Letters|January 22, 2000
Tau gene polymorphisms and apolipoprotein E epsilon4 may interact to increase risk for Alzheimer's diseaseL Lilius, S Froelich Fabre, H Basun, et al.
Dementia and Geriatric Cognitive Disorders|March 25, 2010
Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory studyM Degerman Gunnarsson, M Lindau, A Wall, et al.
Archives of Neurology|May 1, 1997
Clinical characteristics of a chromosome 17-linked rapidly progressive familial frontotemporal dementiaH Basun, O Almkvist, K Axelman, et al.
Annals of Neurology|April 22, 1999
Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progressionM Jensen, J Schröder, M Blomberg, et al.
Journal of Internal Medicine|January 14, 2014
Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD studyY Freund Levi, I Vedin, T Cederholm, et al.
Neurology|October 1, 2008
Serum cystatin C and the risk of Alzheimer disease in elderly menJ Sundelöf, J Arnlöv, E Ingelsson, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Dementia and Geriatric Cognitive Disorders|November 24, 1999
A follow-up study of the family with the Swedish APP 670/671 Alzheimer's disease mutationL O Wahlund, H Basun, O Almkvist, et al.
Annals of the New York Academy of Sciences|July 27, 2000
Inherited frailty. ApoE alleles determine survival after a diagnosis of heart disease or stroke at ages 85+E H Corder, H Basun, L Fratiglioni, et al.
Neuroreport|May 20, 1998
EEG slowing and cerebrospinal fluid tau levels in patients with cognitive declineV Jelic, M Blomberg, T Dierks, et al.
Neuroscience Letters|June 27, 1997
Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau proteinM Lindh, M Blomberg, M Jensen, et al.
Neuroscience Letters|January 22, 2000
Tau gene polymorphisms and apolipoprotein E epsilon4 may interact to increase risk for Alzheimer's diseaseL Lilius, S Froelich Fabre, H Basun, et al.
Dementia and Geriatric Cognitive Disorders|March 25, 2010
Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory studyM Degerman Gunnarsson, M Lindau, A Wall, et al.
Archives of Neurology|May 1, 1997
Clinical characteristics of a chromosome 17-linked rapidly progressive familial frontotemporal dementiaH Basun, O Almkvist, K Axelman, et al.
Annals of Neurology|April 22, 1999
Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progressionM Jensen, J Schröder, M Blomberg, et al.
Journal of Internal Medicine|January 14, 2014
Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD studyY Freund Levi, I Vedin, T Cederholm, et al.
Neurology|October 1, 2008
Serum cystatin C and the risk of Alzheimer disease in elderly menJ Sundelöf, J Arnlöv, E Ingelsson, et al.
Pageof 8